An interventional study of continuous theta burst stimulation(cTBS) in Generalized Anxiety Disorder (GAD), sponsored by Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Central South University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Generalized Anxiety Disorder with a site in China — 17 open to participants now, 17 under way, 3 of them phase 3. Generalized Anxiety Disorder · China.
Among the 24 studies in Generalized Anxiety Disorder with a site in China, this one is the 15th largest by planned enrollment of the 21 interventional ones that give a count, is one of 9 that started in 2026, is one of 12 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 20th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →17 of the 24 studies in Generalized Anxiety Disorder with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–55
Lishu Gao · Sites in China
Ages 18–60 · Healthy volunteers
Fudan University · Sites in China
Ages 18–70 · Women only
Anhui Medical University · Sites in China
Ages 18+
WANG KAI · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 120 across the 21 interventional studies, 120 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 24 have an industry lead sponsor. The 10 most frequent:
Central South University is the lead sponsor of 136 studies on the registry; 32 are open to participants now.
Central South University has 3 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
6 of the studies in Generalized Anxiety Disorder with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07640945Central South UniversityMRI-Guided Accelerated cTBS for Generalized Anxiety Disorder | 2027-01 |
| NCT07330648Anhui Medical UniversityProspective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder | 2027-01-31 |
| NCT07403591Anhui Medical UniversityMapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder | 2027-03-01 |
| NCT07909200Central South UniversityTemporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder | 2027-03-01 |
| NCT07290153Fudan UniversityPsychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 24 studies in Generalized Anxiety Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Generalized Anxiety Disorder (GAD) is a common psychiatric disorder associated with persistent anxiety, functional impairment, and incomplete response to existing treatments. Although transcranial magnetic stimulation (TMS) has shown therapeutic potential in anxiety disorders, conventional treatment schedules often require several weeks and may not provide sufficiently rapid symptom relief. This study aims to evaluate the efficacy and safety of precision-targeted accelerated continuous theta-burst stimulation (cTBS) guided by individualized functional connectivity between the intraparietal sulcus (IPS) and the amygdala in patients with GAD.
Generalized Anxiety Disorder (GAD) is one of the most prevalent psychiatric disorders worldwide and is characterized by excessive and persistent anxiety, impaired psychosocial functioning, and reduced quality of life. Despite the availability of pharmacological and psychological treatments, a substantial proportion of patients continue to experience clinically significant symptoms. Pharmacological therapies often require several weeks before therapeutic benefits emerge, while access to evidence-based psychotherapies remains limited in many settings. Therefore, there is a critical need for novel interventions capable of producing rapid and durable anxiolytic effects.
Transcranial magnetic stimulation (TMS) has emerged as a promising non-invasive neuromodulation technique for the treatment of psychiatric disorders. Continuous theta-burst stimulation (cTBS), a patterned form of repetitive TMS, substantially reduces treatment duration while maintaining efficacy and safety comparable to conventional repetitive TMS protocols. Previous studies have demonstrated therapeutic benefits of cTBS in patients with anxiety disorders; however, conventional treatment courses typically extend over several weeks and may not achieve rapid symptom relief. Accelerated stimulation protocols involving multiple daily treatment sessions over a short period have shown encouraging clinical effects in other psychiatric populations, suggesting potential applicability to anxiety disorders.
Neuroimaging studies have identified the right intraparietal sulcus (IPS) as a key cortical region involved in attentional control, vigilance, salience processing, and anxiety-related arousal. Functional interactions between the IPS and the amygdala are thought to play an important role in regulating emotional and anxiety-related processes. Individual variability in these neural circuits may contribute to heterogeneity in treatment response. Consequently, personalized stimulation targeting based on functional neuroimaging may improve therapeutic outcomes compared with conventional fixed-target approaches.
The present study aims to investigate the efficacy and safety of precision-targeted accelerated cTBS guided by individualized IPS-amygdala functional connectivity in patients with GAD and to explore potential neurobiological mechanisms underlying treatment response. Participants who meet ICD-11 diagnostic criteria for GAD will be randomly assigned in a 1:1:1 ratio to one of three intervention groups: a precision cTBS group, a non-precision cTBS group, or a sham stimulation group.
All participants will receive accelerated cTBS treatment for 5 consecutive days, with five stimulation sessions per day. Each session will deliver 1800 pulses, resulting in a total of 9000 pulses per day, with 50-minute intervals between sessions. Stimulation intensity will be set at 80%-120% of the resting motor threshold. In the precision cTBS group, baseline functional MRI data will be used to identify the right IPS coordinate exhibiting the strongest functional connectivity with the right basolateral amygdala (BLA), and stimulation will be delivered using neuronavigation-guided targeting. In the non-precision cTBS group, stimulation will target a fixed right parietal cortical projection coordinate corresponding to the P4 site reported in previous cranio-cerebral correlation studies of the international 10-20 EEG system. Participants in the sham group will undergo identical procedures using a sham coil.
The primary outcome measure is the change in the total score of the Hamilton Anxiety Rating Scale (HAMA) from baseline to day 5. Secondary outcomes include clinical response and remission rates, changes in relevant clinical symptoms, adverse events occurring during treatment, and neuroimaging indicators. Assessments will be conducted at baseline, during treatment, and at week 2, month 1, and month 2 from baseline to evaluate short-term and sustained treatment effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Undergo precise targeted accelerated cTBS guided by individual right IPS-right BLA functional connectivity. The individual IPS target is located using the Visor2 neuronavigation system, with treatment administered continuously for 5 days, 5 times per day, each session lasting 120 seconds with 1800 pulses, and an interval of 50 minutes between sessions.
Device: continuous theta burst stimulation(cTBS)
Receive non-individualised target cTBS. Use the cortical target corresponding to the P4 site of the international 10-20 EEG system as the stimulation target, with the remaining equipment, stimulation intensity, frequency, treatment course, number of pulses per session, and treatment procedures consistent with the precise cTBS group.
Device: continuous theta burst stimulation(cTBS)
Receive sham cTBS. Apart from using a sham coil with no effective magnetic field output, the coil placement, neuronavigation procedure, number of treatments, treatment duration, and follow-up process are consistent with the precise cTBS group.
Device: continuous theta burst stimulation(cTBS)
Accelerated cTBS treatment was administered over 5 days, five times daily (1800 pulses per session, a total of 9000 pulses per day, with 50-minute intervals between sessions), at a stimulation intensity of 80%-120% of the resting motor threshold. The precise stimulation group targeted locations based on individual baseline functional MRI data, calculating the coordinates of strongest functional connectivity between the right IPS and the right basolateral amygdala (BLA), and implemented via neuronavigation system registration; the non-precise stimulation group targeted the cortical projection coordinates of the P4 electrode site according to the international 10-20 EEG system; the sham stimulation group used the same parameters but with a sham coil.
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score From Baseline to Day 5
Anxiety symptom severity will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. The outcome will be calculated as the change in HAMA total score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Clinical Response Rate
Clinical response will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical response is defined as a reduction of at least 50% in HAMA total score compared with baseline.
Time frame: Day 3, Day 5, Week 2, Month 1, and Month 2 from baseline
Clinical Remission Rate
Clinical remission will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical remission is defined as a HAMA total score of 7 or less at the corresponding assessment time point.
Time frame: Day 3 , Day 5 , Week 2, Month 1, and Month 2 from baseline
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score From Baseline
Anxiety symptom severity will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. The outcome will be calculated as the change in HAMA total score from baseline to each post-baseline assessment time point.
Time frame: Baseline, Day 3, Week 2, Month 1, and Month 2
Change in 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score From Baseline
Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), a clinician-administered scale with a total score range of 0 to 52. Higher scores indicate greater depressive symptom severity, which represents a worse outcome. The outcome will be calculated as the change in HAMD-17 total score from baseline to each post-baseline assessment time point.
Time frame: Baseline, Day 3, Day 5, Week 2, Month 1, and Month 2 from baseline
Change in Beck Scale for Suicide Ideation (BSI) Score From Baseline
Suicidal ideation will be assessed using the Beck Scale for Suicide Ideation (BSI), a 19-item scale with a total score range of 0 to 38. Higher scores indicate more severe suicidal ideation, which represents a worse outcome. The outcome will be calculated as the change in BSI score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Generalized Anxiety Disorder-7 (GAD-7) Score From Baseline
Anxiety symptom severity will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report questionnaire with a total score range of 0 to 21. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. The outcome will be calculated as the change in GAD-7 score from baseline to each post-baseline assessment time point.
Time frame: Baseline, Day 3, Day 5, Week 2 and Month 1 from baseline
Change in Patient Health Questionnaire-15 (PHQ-15) Score From Baseline
Somatic symptom severity will be assessed using the Patient Health Questionnaire-15 (PHQ-15), a 15-item self-report questionnaire with a total score range of 0 to 30. Higher scores indicate greater somatic symptom severity, which represents a worse outcome. The outcome will be calculated as the change in PHQ-15 score from baseline to each post-baseline assessment time point.
Time frame: Baseline, Day 3, Day 5, Week 2 and Month 1 from baseline
Change in Patient Health Questionnaire-9 (PHQ-9) Score From Baseline
Depressive symptom severity will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report questionnaire with a total score range of 0 to 27. Higher scores indicate greater depressive symptom severity, which represents a worse outcome. The outcome will be calculated as the change in PHQ-9 score from baseline to each post-baseline assessment time point.
Time frame: Baseline, Day 3, Day 5, Week 2 and Month 1 from baseline
Change in Pittsburgh Sleep Quality Index (PSQI) Score From Baseline
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a self-report questionnaire with a global score range of 0 to 21. Higher scores indicate poorer sleep quality, which represents a worse outcome. The outcome will be calculated as the change in PSQI global score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Penn State Worry Questionnaire (PSWQ) Score From Baseline
Worry severity will be assessed using the Penn State Worry Questionnaire (PSWQ), a 16-item self-report questionnaire with a total score range of 16 to 80. Higher scores indicate greater worry severity, which represents a worse outcome. The outcome will be calculated as the change in PSWQ score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Intolerance of Uncertainty Scale (IUS) Score From Baseline
Intolerance of uncertainty will be assessed using the Intolerance of Uncertainty Scale (IUS), a 27-item self-report questionnaire with a total score range of 27 to 135. Higher scores indicate greater intolerance of uncertainty, which represents a worse outcome. The outcome will be calculated as the change in IUS score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Cognitive Test Performance From Baseline to Day 5
Cognitive function will be assessed using neurocognitive tests administered in this study. The score range depends on the specific cognitive test or task. For accuracy-based cognitive measures, higher scores indicate better cognitive performance, which represents a better outcome; for time-based measures such as reaction time, higher values indicate slower performance, which represents a worse outcome. The outcome will be calculated as the change in cognitive test performance from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in State-Trait Anxiety Inventory (STAI) Score From Baseline
Anxiety symptoms and anxiety proneness will be assessed using the State-Trait Anxiety Inventory (STAI), a 40-item self-report questionnaire consisting of the State Anxiety and Trait Anxiety subscales. Each subscale has a score range of 20 to 80. Higher scores indicate greater anxiety, which represents a worse outcome. The outcome will be calculated as the change in STAI score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Perceived Stress Scale-10 (PSS-10) Score From Baseline
Perceived stress will be assessed using the Perceived Stress Scale-10 (PSS-10), a 10-item self-report questionnaire with a total score range of 0 to 40. Higher scores indicate higher perceived stress, which represents a worse outcome. The outcome will be calculated as the change in PSS-10 score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Ruminative Responses Scale (RRS) Score From Baseline
Rumination will be assessed using the Ruminative Responses Scale (RRS), a 22-item self-report questionnaire with a total score range of 22 to 88. Higher scores indicate greater rumination, which represents a worse outcome. The outcome will be calculated as the change in RRS score from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Anxiety and Depression Visual Analogue Scale Scores From Baseline
Subjective anxiety and depression severity will be assessed using visual analogue scale ratings for anxiety and depression. Each visual analogue scale score ranges from 0 to 10, with higher scores indicating greater subjective symptom severity, which represents a worse outcome. The outcome will be calculated as the change in visual analogue scale scores from baseline to each post-baseline assessment time point.
Time frame: Baseline, Day 1, Day 3, Day 5 and Week 2 from baseline
Treatment-Emergent Side Effects During the Intervention and Follow-up Period
Treatment-emergent side effects will be assessed using a physical treatment side-effect assessment that records the presence, type, severity, and relationship to the study intervention of adverse events. This outcome will be summarized as the occurrence and severity of treatment-emergent side effects during the intervention and follow-up period; higher severity indicates a worse safety outcome.
Time frame: Day 1, Day 3, Day 5 and Week 2 from baseline
Change in Heart Rate Variability From Baseline to Day 5
Heart rate variability will be assessed to evaluate autonomic nervous system function. Heart rate variability parameters may include time-domain and frequency-domain measures such as the standard deviation of normal-to-normal intervals and the root mean square of successive differences. The expected range depends on the specific heart rate variability parameter. In general, higher heart rate variability reflects better autonomic flexibility and may represent a better physiological outcome. The outcome will be calculated as the change in heart rate variability measures from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Change in Magnetic Resonance Imaging Measures From Baseline to Day 5
Brain structural and/or functional measures will be assessed using magnetic resonance imaging. The specific values and ranges depend on the imaging modality and derived measure, such as structural, functional connectivity, or brain network metrics. Interpretation will depend on the specific magnetic resonance imaging measure analyzed. The outcome will be calculated as the change in magnetic resonance imaging measures from baseline to Day 5.
Time frame: Baseline and Day 5 (End of Treatment)
Dysfunctional Attitudes Scale (DAS) Score at Baseline
Dysfunctional attitudes will be assessed using the Dysfunctional Attitudes Scale (DAS), a 40-item self-report scale with a total score range of 40 to 280. Higher scores indicate more dysfunctional attitudes, which represents a worse psychological profile. This measure will be assessed at baseline.
Time frame: Baseline
Childhood Trauma Questionnaire (CTQ) Score at Baseline
Childhood trauma exposure will be assessed using the Childhood Trauma Questionnaire (CTQ), a 25-item self-report questionnaire with a total score range of 25 to 125. Higher scores indicate greater childhood trauma exposure, which represents a worse psychosocial profile. This measure will be assessed at baseline.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.
Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 7 months is below that.
Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →